Epilepsy Clinical Trials

Find Epilepsy Clinical Trials Near You

Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies

Status: Recruiting
Location: See location...
Intervention Type: Genetic
Study Type: Observational
SUMMARY

Brain somatic mutations affecting genes of the mTOR signaling pathway are a well-established cause of cortical malformations, including focal cortical dysplasia and hemimegalencephaly. Somatic mutations in SLC35A2 have been identified in mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE), while activating somatic mutations in the SHH pathway are associated with hypothalamic hamartomas. This study aims to identify brain-restricted somatic mutations through the analysis of paired blood-brain samples and to assess their functional impact in children with drug-resistant focal epilepsy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 3 months
Maximum Age: 25
Healthy Volunteers: f
View:

• Children with focal drug-resistant epilepsy including Focal Cortical Dysplasia, Hemimegalencephaly, Tuberous Sclerosis, Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE), Hypothalamic Hamartomas, Sturge-Weber syndrome, Rasmussen encephalitis, gliomas

• Their parents who have signed informed consent 1) for their child's participation (for parents) and 2) for themselves

• Social security coverage or foreign regime recognized in France

Locations
Other Locations
France
Fondation Ophtalmologique Adolphe de Rothschld
RECRUITING
Paris
Contact Information
Primary
Amelie YAVCHITZ, MD
ayavchitz@for.paris
+33 1 48 03 64 54
Backup
Mathilde CHIPAUX, MD, PhD
mchipaux@for.paris
+33 1 48 03 69 43
Time Frame
Start Date: 2015-12-17
Estimated Completion Date: 2031-12
Participants
Target number of participants: 450
Treatments
Children undergoing epilepsy surgery at the Rothschild Foundation, Paris.
Sequencing of paired blood-brain DNA samples, SEEG electrodes
Sponsors
Leads: Fondation Ophtalmologique Adolphe de Rothschild

This content was sourced from clinicaltrials.gov